HK1218263A1 - 大环rip2激酶抑制剂 - Google Patents

大环rip2激酶抑制剂 Download PDF

Info

Publication number
HK1218263A1
HK1218263A1 HK16106342.4A HK16106342A HK1218263A1 HK 1218263 A1 HK1218263 A1 HK 1218263A1 HK 16106342 A HK16106342 A HK 16106342A HK 1218263 A1 HK1218263 A1 HK 1218263A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
het
cycloalkyl
optionally
halogen
Prior art date
Application number
HK16106342.4A
Other languages
English (en)
Chinese (zh)
Inventor
．布洛姆
P．M．F．布洛姆
．霍夫拉克
J．M．C．J．霍夫拉克
．本德裡特爾
P．A．R．本德里特尔
Original Assignee
昂科迪塞恩股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1304714.7A external-priority patent/GB201304714D0/en
Application filed by 昂科迪塞恩股份有限公司 filed Critical 昂科迪塞恩股份有限公司
Publication of HK1218263A1 publication Critical patent/HK1218263A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16106342.4A 2013-03-15 2014-03-14 大环rip2激酶抑制剂 HK1218263A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2013066732 2013-03-15
EPPCT/EP2013/066732 2013-03-15
GBGB1304714.7A GB201304714D0 (en) 2013-03-15 2013-03-15 Macrocyclic RIP2 Kinase inhibitors
GB1304714.7 2013-03-15
PCT/EP2014/055139 WO2014140299A1 (en) 2013-03-15 2014-03-14 Macrocyclic rip2 kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1218263A1 true HK1218263A1 (zh) 2017-02-10

Family

ID=50342296

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106342.4A HK1218263A1 (zh) 2013-03-15 2014-03-14 大环rip2激酶抑制剂

Country Status (13)

Country Link
US (1) US20160024114A1 (enExample)
JP (1) JP2016510796A (enExample)
KR (1) KR20150133765A (enExample)
CN (1) CN105228625A (enExample)
AU (1) AU2014230111A1 (enExample)
BR (1) BR112015022982A2 (enExample)
CA (1) CA2906257A1 (enExample)
EA (1) EA201591773A1 (enExample)
HK (1) HK1218263A1 (enExample)
IL (1) IL241250A0 (enExample)
MX (1) MX2015012526A (enExample)
SG (1) SG11201507594YA (enExample)
WO (1) WO2014140299A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146651A1 (en) * 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
EP3458072B1 (en) 2016-05-19 2020-09-30 Universiteit Antwerpen Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases
JP2019527230A (ja) * 2016-07-28 2019-09-26 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 大環状キナーゼ阻害剤
KR102719387B1 (ko) * 2017-01-26 2024-10-21 한미약품 주식회사 이미다조피리다진 화합물
EP3770161B1 (en) * 2018-04-16 2022-08-24 Shenzhen TargetRx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
UY39061A (es) * 2020-01-31 2022-01-31 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
CN117659043A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种大环咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
WO2025212514A2 (en) * 2024-04-02 2025-10-09 Interline Therapeutics, Inc. Methods of treating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ120999A0 (en) * 1999-06-25 1999-07-22 Industrial Automation Services Pty Ltd Vibration suppressing piston
JP2004089182A (ja) * 2002-06-24 2004-03-25 Takeda Chem Ind Ltd がんの予防・治療剤
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
EA025881B1 (ru) * 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
EP2760453B1 (en) * 2011-09-30 2016-05-25 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
CN105209040A (zh) * 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
CN105143232A (zh) * 2013-03-15 2015-12-09 益普生制药股份有限公司 大环的lrrk2激酶抑制剂

Also Published As

Publication number Publication date
EA201591773A1 (ru) 2016-01-29
WO2014140299A1 (en) 2014-09-18
KR20150133765A (ko) 2015-11-30
IL241250A0 (en) 2015-11-30
US20160024114A1 (en) 2016-01-28
SG11201507594YA (en) 2015-10-29
MX2015012526A (es) 2016-04-26
CA2906257A1 (en) 2014-09-18
BR112015022982A2 (pt) 2017-07-18
CN105228625A (zh) 2016-01-06
JP2016510796A (ja) 2016-04-11
AU2014230111A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2016290820B2 (en) Cot modulators and methods of use thereof
HK1218263A1 (zh) 大环rip2激酶抑制剂
CA2767648C (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
WO2018153373A1 (zh) Fgfr抑制剂及其应用
HK1219057A1 (zh) 大环的盐可诱导的激酶抑制剂
WO2020078362A1 (zh) 一类咪唑并芳环类化合物的制备和应用
CN112771049B (zh) Fgfr4抑制剂及其应用
CN106687464B (zh) 大环rip2激酶抑制剂
TW201833113A (zh) 作為Ｐ１３Ｋδ抑制劑之咪唑并［１，５－Ａ］吡衍生物
TW202438054A (zh) 作為ＭＴＡ－協同ＰＲＭＴ５抑制劑的５－胺基－６，８－二氫－１Ｈ－呋喃并［３，４－ｄ］吡咯并［３，２－ｂ］吡啶－２－甲醯胺衍生物
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN110078743A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
HK1232862A1 (en) Macrocyclic rip2 kinase inhibitors
HK1232862B (zh) 大环rip2激酶抑制剂
EP2968325A1 (en) Macrocyclic rip2 kinase inhibitors
WO2023083373A1 (zh) 作为Src抑制剂的化合物
TW202540103A (zh) 雜芳基衍生物化合物及其用途
EA050235B1 (ru) Соединения и их применение в виде ингибиторов gpr183
HK40042846B (zh) Fgfr4抑制剂及其应用
NZ730758B2 (en) Macrocyclic rip2 kinase inhibitors